Research Industry sponsorship bias in cost effectiveness analysis: registry based analysis Feng Xie, Ting Zhou BMJ 2022; 377 doi: https://doi.org/10.1136/bmj-2021-069573 (Published 22 June 2022)Cite this as: BMJ 2022;377:e069573 Abstract Objective To assess the association between industry sponsorship (drug, medical device, and biotechnology companies) and cost effectiveness results in cost effectiveness analysis (CEA). Design Registry based an...

ICU Management & Practice, Volume 22 - Issue 1, 2022 Diagnostic and Prognostic Value of Estimated Plasma Volume Status An overview of estimated plasma volume (ePVS), recent evidence supporting the association of ePVS with clinical congestion and whether it can help improve outcomes in patients with heart failure (HF). Plasma volume (PV) is the level of intravascular fluid minus the red blood cells, white blood cells and platelets. PV in heart failure (HF...

Brief Report  November 19, 2020 Eye Protection for Patients With COVID-19 Undergoing Prolonged Prone-Position Ventilation Lucy Sun, Maggie Hymowitz, Howard D. Pomeranz JAMA Ophthalmol. 2021;139(1):109-112. doi:10.1001/jamaophthalmol.2020.4988 Key Points Question  What ophthalmic abnormalities are present in patients with coronavirus disease 2019 in the intensive care unit requiring prolonged prone-position ventilation? Findings &nb...

Research Special Paper Political environment and mortality rates in the United States, 2001-19: population based cross sectional analysis Haider J Warraich, Pankaj Kumar, Khurram Nasir, et al BMJ 2022; 377 doi: https://doi.org/10.1136/bmj-2021-069308 (Published 07 June 2022)Cite this as: BMJ 2022;377:e069308 Abstract Objective To assess recent trends in age adjusted mortality rates (AAMRs) in the United States based on county level presidential vo...

Drug Dosing Recommendations for Obese COVID-19 Patients Obesity is highly prevalent in patients who are hospitalised with COVID-19. It is a widely recognised risk factor for severe COVID-19 infection with a greater risk for mortality compared with non-obese patients. With each 1 kg/m2 increase in body mass index, the risk for severe infection increases by 9% and mortality by 6%.  While there are evidence-basedevidence-based guidelines to treat patients...

ARTICLES| VOLUME 399, ISSUE 10344, P2351-2380, JUNE 25, 2022 Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis COVID-19 Cumulative Infection Collaborators Lancet 2022; 399: 2351-2380 Published:April 08, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00484-6 Summary Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection ra...

Medical News & Perspectives  June 1, 2022 Challenges of Deciding Whether and How to Update COVID-19 Vaccines to Protect Against Variants Rita Rubin JAMA. Published online June 1, 2022. doi:10.1001/jama.2022.9367 Seasonal influenza vaccines are updated every year, depending on what strains are circulating globally, leaving many people—especially those who still contracted COVID-19 after 2 booster shots—wondering why vaccines against SARS-C...

US Preventive Services Task Force  Evidence Report June 21, 2022 Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Elizabeth A. O’Connor, Corinne V. Evans, Ilya Ivlev, et al JAMA. 2022;327(23):2334-2347. doi:10.1001/jama.2021.15650 Abstract Importance  Cardiovascular disease and cancer are the ...

Research Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study Kuan Ken Lee, Dimitrios Doudesis, Mohamed Anwar, et al BMJ 2022; 377 doi: https://doi.org/10.1136/bmj-2021-068424 (Published 13 June 2022)Cite this as: BMJ 2022;377:e068424 Abstract Objectives To evaluate the diagnostic performance of N-terminal pro-B-...

Abionic's Unique Sepsis Detection Solution Based in Switzerland, Abionic is an in vitro diagnostic company, uniquely positioned at the intersection of medical technology, biotechnology and nanotechnology. The company has developed an unparalleled nanofluidic technology-based platform, the abioSCOPE® to offer patients fast blood test results right at the Point-of-Care (PoC). The abioSCOPE® is a compact and ultra-fast diagnostic solution, prov...